Webinar live date: Tuesday 10 December 2019 07:00 [PST] 10:00 [EST] 15:00 [GMT]. LC–MS based large molecule bioanalysis platform was developed, validated and applied for drug screening and preclinical pharmacokinetics.
Webinar now available on demand. The aim of DMPK is to enable scientists to learn the safety and efficacy of new molecular entities. HRMS is an important analytical tool used to study DMPK that continues to gain traction when quantifying molecules.
Webinar now available on demand. Absolute quantitation of intact biotherapeutics is enabled through advances in immunocapture techniques coupled to LC–MS.
Webinar live date: Thursday 12 December 2019 07:00 [PST] 10:00 [EST] 15:00 [GMT]. On December 12, join us as we discuss, with supporting case studies, how hybridization ELISA can be an effective approach to quantify antisense oligonucleotides in circulation and in their targeted tissue.
Panel discussion available on demand. In this free panel discussion, our experts will provide insights into their own research using oligonucleotides, including the most common challenges encountered, key trends they have seen as the field develops and their opinions on the future outlook of the technology.
Webinar now available on demand. Learn about the sensitivity gains afforded by microflow chromatography vs high-flow and what potential this has for Met ID. See how this translates to stronger spectra in turn resulting in more metabolites being identified and characterized.
Thank you everyone who attended our live webinar ‘Exploratory biomarker testing: to qualify or validate the assay? The latest scientific and regulatory considerations for biomarker validation‘ in association with BioAgilytix.
Webinar available on demand. A ‘tips and tricks’ approach to understanding and optimizing chromatography of oligonucleotides. Taking into consideration the nature of the oligonucleotide you are interested in, you will be able to make informed choices about what approach to use.
Webinar available on demand. An overview of Gyrolab immunoassays and their utility in CMC target binding assays for batch release and stability assessment. Also, for preclinical and clinical PK analysis with a view to transferring assays to a CRO.
Webinar available on demand. In this free panel discussion, our experts will provide insights into their own research using ligand binding assays including the challenges they have had to overcome, key trends they have seen and their future outlook on the development of this field.
Mass Spectrometry (LC–MS/MS and LC–HRMS) approaches for bioanalysis of antibody–drug conjugates and applications will be presented.
Researchers have designed a non-invasive and inexpensive chip-based optical biosensor with increased sensitivity to detect the presence and progression of cancerous tumors. The cancer protein biomarker S100A4 was detected at concentrations of 300 picomolar in a synthetic urine sample.
A study carried out by researchers based at the University of Cambridge (UK) and biotechnology company SomaLogic (CO, USA) has demonstrated that large-scale measurements of proteins in a single blood test could predict risk factors for a range of diseases.
Researchers from Dyno Therapeutics (MA, USA) and Harvard University (MA, USA) have reported a comprehensive machine-guided approach to produce improved adeno-associated virus capsids for gene therapy delivery.
A rapid mobile-based assay for determination of inflammation through quantification of alpha-1-acid glycoprotein has been developed.
As part of our Spotlight on HRMS in DMPK, we carried out a survey to gain an insight into the trends, challenges and developments associated with using HRMS for DMPK studies. We would like to thank everyone who was able to share their thoughts by taking part in the survey – you can see the results below in our infographic.